Pliant Therapeutics Inc (STU:9PT)
€ 12.5 -0.7 (-5.3%) Market Cap: 778.32 Mil Enterprise Value: 448.21 Mil PE Ratio: 0 PB Ratio: 2.37 GF Score: 36/100

Pliant Therapeutics Inc at RBC Capital Markets Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium (Virtual) Transcript

Oct 07, 2022 / 02:20PM GMT
Release Date Price: €22.2 (-2.63%)
Greg Renza;Brian Abrahams
RBC Capital Markets - Analyst;RBC Capital Markets

Good morning and welcome, everyone, to another RBC Expert Insights session. My name is Greg Renza, one of the biotechnology equity research analysts here, and I'm joined alongside my colleague Brian Abrahams, and we're pleased to have today a Pulmonary and Lung Disease Mini-Symposium. We do have an exciting lineup over the next several hours across the pulmonary space to hear from development experts and clinical and research experts across the space.

We're kicking off the sessions with some company presentations first from Pliant and then from aTyr, and then leading into a nice early afternoon of KOL and expert sessions on sarcoidosis, IPF, scleroderma, ILD, KRAS in lung cancer, as well as a session to wrap up the day on long COVID. As always, if you have any questions for us, the speakers, do please feel free to reach out, use the link or e-mail us. These are quick sessions, a lot to cover.

And with that, we will get started and take it away over to Brian. Thank you very much.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot